Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Galen Hldgs (WCRX)

  Print      Mail a friend

Friday 21 December, 2001

Galen Hldgs

Submission to FDA

Galen Holdings PLC
21 December 2001

Craigavon, Northern Ireland/Rockaway, NJ                      December 21, 2001

 Galen submits New Drug Application for Intravaginal Ring to US Food and Drug

Craigavon, Northern Ireland, UK / Rockaway, New Jersey, USA...December 21,
2001...Galen Holdings PLC (LSE: GAL.L, Nasdaq: GALN) today announced that it
has completed the submission of its New Drug Application (NDA) to the U.S.
Food and Drug Administration (FDA) for its intravaginal ring estrogen
replacement therapy, Estrace VR(R).

The product, for hormone replacement therapy, was approved for use in the
United Kingdom earlier this year and is marketed under the brand name Menoring
(R).  Submission to the European regulatory authorities via the Mutual
Recognition Procedure is in progress.

Roger Boissonneault, Chief Executive of Galen Holdings, said: 'The submission
of the NDA is an important step towards the commercialisation of our IVR drug
delivery platform in the United States.  We look forward to working with the
various regulatory authorities over the coming months.'


Notes to Editors

Galen is an integrated specialty pharmaceutical company based in Craigavon,
Northern Ireland and Rockaway, New Jersey, USA.  Galen develops, acquires and
manufactures branded prescription pharmaceutical products which are promoted
by the Company's sales and marketing organizations in the UK, Ireland and the
US.  Galen's Pharma Services division supplies and distributes clinical trial
materials internationally, operates a drug reconciliation business and
provides computer-based interactive voice response systems to permit
theefficient management of worldwide clinical trials. The Pharma Services
division also provides 'bench-to-pilot-scale' custom chemical design and
synthesis services to the research-based pharmaceutical industry.


Statements made in this press release include forward-looking statements made
pursuant to the safe harbor provisions of the Securities Litigation Reform Act
of 1995.  Such statements, including those relating to financial expectations
for the fiscal year 2001 and beyond, involve certain risks and uncertainties
that could cause actual results to differ materially from those in the forward
looking statements, including, but not limited to, the company's dependence on
key products, risks associated with product development and manufacturing, the
uncertainty of future financial results and fluctuations in operating results,
dependence on the Company's acquisition strategy, new product introductions,
currency fluctuations and other risks described from time to time in the
Company's SEC filings.  These forward-looking statements represent the
judgment of the Company, as of the date of this release, and the Company
disclaims any intent or obligation to update these forward-looking statements.
  Information on other significant potential risks and uncertainties not
discussed herein may be found in the Company's filings with the Securities and
Exchange Commission including its Form 20F for the year ended September 30,
2000, when filed, and all information previously filed by the Company's
wholly-owned subsidiary, Warner Chilcott plc, including Warner Chilcott plc's,
definitive proxy statement filed with the SEC on August 8, 2000.


Dr. John King, Chairman, Galen Holdings PLC

Craigavon, Northern Ireland, UK


Roger Boissonneault, CEO, Galen Holdings PLC

Rockaway, New Jersey, USA


Andrew Dowler/Fiona Noblet, Financial Dynamics

+44-(0)20-7831 3113


a d v e r t i s e m e n t